| 1. |
- Abat, E., et al.
(författare)
-
Study of the response of the ATLAS central calorimeter to pions of energies from 3 to 9 GeV
- 2009
-
Ingår i: Nuclear Instruments & Methods in Physics Research. Section A: Accelerators, Spectrometers, Detectors, and Associated Equipment. - : Elsevier BV. - 0167-5087 .- 0168-9002 .- 1872-9576. ; 607:2, s. 372-386
-
Tidskriftsartikel (refereegranskat)abstract
- A fully instrumented slice of the ATLAS central detector was exposed to test beams from the SPS (Super Proton Synchrotron) at CERN in 2004. in this paper, the response of the central calorimeters to pions with energies in the range between 3 and 9 GeV is presented. The linearity and the resolution of the combined calorimetry (electromagnetic and hadronic calorimeters) was measured and compared to the prediction of a detector simulation program using the toolkit Geant 4. (C) 2009 Elsevier B.V. All rights reserved.
|
|
| 2. |
- Aapro, M, et al.
(författare)
-
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
- 2008
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 1569-8041 .- 0923-7534. ; 19:3, s. 420-432
-
Tidskriftsartikel (refereegranskat)abstract
- Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in patients, and have substantially decreased the prevalence of such events since their introduction. Today, a broad range of BP with differences in potency, efficacy, dosing, and administration as well as approved indications is available. In addition, results of clinical trials investigating the efficacy of BP in cancer treatment-induced bone loss (CTIBL) have been recently published. The purpose of this paper is to review the current evidence on the use of BP in solid tumours and provide clinical recommendations. An interdisciplinary expert panel of clinical oncologists and of specialists in metabolic bone diseases assessed the widespread evidence and information on the efficacy of BP in the metastatic and nonmetastatic setting, as well as ongoing research on the adjuvant use of BP. Based on available evidence, the panel recommends amino-bisphosphonates for patients with metastatic bone disease from breast cancer and zoledronic acid for patients with other solid tumours as primary disease. Dosing of BP should follow approved indications with adjustments if necessary. While i.v. administration is most often preferable, oral administration (clodronate, IBA) may be considered for breast cancer patients who cannot or do not need to attend regular hospital care. Early-stage cancer patients at risk of developing CTIBL should be considered for preventative BP treatment. The strongest evidence in this setting is now available for ZOL. Overall, BP are well-tolerated, and most common adverse events are influenza-like syndrome, arthralgia, and when used orally, gastrointestinal symptoms. The dose of BP may need to be adapted to renal function and initial creatinine clearance calculation is mandatory according to the panel for use of any BP. Subsequent monitoring is recommended for ZOL and PAM, as described by the regulatory authority guidelines. Patients scheduled to receive BP (mainly every 3-4 weeks i.v.) should have a dental examination and be advised on appropriate measures for reducing the risk of jaw osteonecrosis. BP are well established as supportive therapy to reduce the frequency and severity of skeletal complications in patients with bone metastases from different cancers.
|
|
| 3. |
- Lacour, S., et al.
(författare)
-
The limb-darkened Arcturus : imaging with the IOTA/IONIC interferometer
- 2008
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 485:2, s. 561-570
-
Tidskriftsartikel (refereegranskat)abstract
- Aims. We undertook an H band interferometric examination of Arcturus, a star frequently used as a spatial and spectral calibrator. Methods. Using the IOTA 3 telescope interferometer, we performed spectro-interferometric observations (R approximate to 35) of Arcturus. Atmospheric models and prescriptions were fitted to the data to derive the brightness distribution of the photosphere. Image reconstruction was performed using two software algorithms: WISARD and MIRA. Results. An achromatic power law proved to be a good model of the brightness distribution, with a limb darkening compatible with the one derived from atmospheric model simulations using our mARCS model. A Rosseland diameter of 21.05 +/- 0.21 was derived, corresponding to an effective temperature of T-eff = 4295 +/- 26 K. No companion was detected from the closure phases, with an upper limit on the brightness ratio of 8 x 10(-4) at 1 AU. The dynamic range at such distance from the photosphere was established as 1.5 x 10(-4) (1 sigma rms). An upper limit of 1.7 x 10(-3) was also derived for the level of brightness asymmetries present in the photosphere.
|
|
